Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one 
from Friedreich ataxia, were treated with a placebo i.v. infusion during the 
first day and with TRH-T i.v. infusion at a rate of 2 mg/h for 8 h daily (total 
daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) 
and EKG monitorings were performed during 3 days infusion. Blood samples were 
collected for endocrinological evaluations. The neurological evaluation after 
acute TRH-T treatment showed an objective improvement in 3 of the 8. We found 
significantly higher values of systolic (max. difference of 10.1 mm Hg) and 
diastolic (max. difference of 8.8 mm Hg) BP than during placebo, beginning from 
the 5th h of the infusion (p less than 0.05). A trend in progressive increase of 
the heart rate (HR) reached statistical significance (p less than 0.01) at the 
8th h of the second TRH-T infusion. The cardiovascular changes during the i.v. 
continuous TRH-T infusions were clinically irrelevant and never required the 
interruption of the treatment.